MDRNA has appeared on the horizon as another RNAi-focused company hoping to make good on the promise of using RNA interference to develop safe and effective RNA-based therapeutics. As part of a shift in business focus, the 55-person Bothell, Wash.-based company changed its name this summer from Nastech to MDRNA. Run by CEO Michael French, MDRNA's goal is to develop novel compounds and unique drug delivery techniques, aiming to get its lead candidate into phase I clinical trials by the end of 2009.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.